MRC Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU, UK.
Cell Mol Life Sci. 2018 Apr;75(8):1307-1324. doi: 10.1007/s00018-017-2713-8. Epub 2017 Nov 27.
The prevalence of liver diseases is increasing globally. Orthotopic liver transplantation is widely used to treat liver disease upon organ failure. The complexity of this procedure and finite numbers of healthy organ donors have prompted research into alternative therapeutic options to treat liver disease. This includes the transplantation of liver cells to promote regeneration. While successful, the routine supply of good quality human liver cells is limited. Therefore, renewable and scalable sources of these cells are sought. Liver progenitor and pluripotent stem cells offer potential cell sources that could be used clinically. This review discusses recent approaches in liver cell transplantation and requirements to improve the process, with the ultimate goal being efficient organ regeneration. We also discuss the potential off-target effects of cell-based therapies, and the advantages and drawbacks of current pre-clinical animal models used to study organ senescence, repopulation and regeneration.
肝脏疾病的患病率在全球范围内呈上升趋势。原位肝移植被广泛用于治疗肝衰竭。由于该手术的复杂性和有限的健康器官供体数量,促使人们研究替代治疗方案来治疗肝脏疾病。这包括移植肝细胞以促进再生。虽然成功,但常规供应高质量的人类肝细胞是有限的。因此,正在寻找可再生和可扩展的细胞来源。肝祖细胞和多能干细胞为可用于临床的潜在细胞来源提供了可能。这篇综述讨论了肝细胞移植的最新方法以及改进该过程的要求,最终目标是实现有效的器官再生。我们还讨论了细胞治疗的潜在脱靶效应,以及目前用于研究器官衰老、再群体化和再生的临床前动物模型的优缺点。